BMY – bristol-myers squibb company (US:NASDAQ)
Stock Stats
News
12/4
08:53 pm
bmy
Low
Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) [Yahoo! Finance]
12/4
08:15 pm
bmy
Low
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
12/4
08:45 am
bmy
Low
Bristol Myers Squibb (NYSE:BMY) had its "sector perform" rating reaffirmed by analysts at Scotiabank.
12/4
12:08 am
bmy
Low
How faster decisions can transform patient care in Canada [Globe and Mail, The (Toronto, Canada)]
12/3
04:14 pm
bmy
Low
Bristol Myers Squibb (NYSE:BMY) was given a new $65.00 price target on by analysts at Truist Financial Corporation.
10/31/2025
04:03 pm
bmy
-0.1%
BEAT
10/30/2025
04:03 pm
bmy
1.0%
BEAT
10/30/2025
09:06 am
bmy
5.5%
BEAT
7/31/2025
04:03 pm
bmy
2.1%
BEAT
12/4
02:58 pm
Maintains
Sector Perform
Sector Perform
Scotiabank
Low
0.2%
12/4
02:58 pm
Maintains
Sector Perform
Sector Perform
Scotiabank
Low
0.2%
12/4
08:45 am
Reiterates
Sector Perform
Sector Perform
Scotiabank
Low
2.3%
12/4
08:45 am
Reiterates
Sector Perform
Sector Perform
Scotiabank
Low
2.3%
12/2
01:12 pm
Maintains
Neutral
Neutral
Goldman Sachs
Low
-0.4%
11/18
04:42 pm
bmy
Medium
Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 17
11/12
10:07 am
bmy
Low
Form CERT BRISTOL MYERS SQUIBB CO
11/10
04:46 pm
bmy
Medium
Form 8-A12B BRISTOL MYERS SQUIBB CO
11/10
04:07 pm
bmy
Medium
Form 8-K BRISTOL MYERS SQUIBB CO For: Oct 31
11/5
04:51 pm
bmy
Low
Form FWP BRISTOL MYERS SQUIBB CO Filed by: BRISTOL MYERS SQUIBB CO
Show more
Top News Gainers
7/24 Bristol-Myers releases mixed Opdivo lung cancer results [Reuters] 10.2%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
8/15 What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes] 2.7%
Top News Decliners
6/24 Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma -7.8%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
4/20 Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool] -3.5%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3